Equities Analysts Issue Forecasts for USNA Q3 Earnings

USANA Health Sciences, Inc. (NYSE:USNA) – Sidoti Csr increased their Q3 2025 earnings per share (EPS) estimates for USANA Health Sciences in a note issued to investors on Wednesday, February 26th. Sidoti Csr analyst A. Lebiedzinski now forecasts that the company will post earnings per share of $0.72 for the quarter, up from their previous forecast of $0.70. The consensus estimate for USANA Health Sciences’ current full-year earnings is $2.45 per share. Sidoti Csr also issued estimates for USANA Health Sciences’ Q3 2025 earnings at $0.72 EPS, Q3 2026 earnings at $0.98 EPS and Q3 2026 earnings at $0.98 EPS.

USANA Health Sciences (NYSE:USNA) last announced its quarterly earnings results on Tuesday, February 25th. The company reported $0.64 EPS for the quarter, beating the consensus estimate of $0.49 by $0.15. USANA Health Sciences had a return on equity of 10.64% and a net margin of 6.30%. The company had revenue of $213.61 million for the quarter, compared to the consensus estimate of $208.82 million.

Several other equities research analysts also recently issued reports on the stock. DA Davidson lowered their price objective on shares of USANA Health Sciences from $38.00 to $36.00 and set a “neutral” rating on the stock in a research note on Thursday. StockNews.com downgraded shares of USANA Health Sciences from a “strong-buy” rating to a “buy” rating in a research note on Friday, February 14th. Finally, Sidoti downgraded shares of USANA Health Sciences from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, February 18th.

USANA Health Sciences Stock Up 3.2 %

Shares of USNA stock opened at $29.55 on Friday. The business’s 50 day moving average is $33.50 and its two-hundred day moving average is $36.56. The company has a market cap of $563.22 million, a PE ratio of 10.44, a price-to-earnings-growth ratio of 0.93 and a beta of 0.87. USANA Health Sciences has a 12 month low of $27.71 and a 12 month high of $50.32.

Institutional Investors Weigh In On USANA Health Sciences

Several hedge funds and other institutional investors have recently modified their holdings of the stock. Martingale Asset Management L P grew its stake in shares of USANA Health Sciences by 2.1% in the third quarter. Martingale Asset Management L P now owns 16,732 shares of the company’s stock worth $634,000 after acquiring an additional 340 shares during the last quarter. KBC Group NV lifted its position in USANA Health Sciences by 96.6% in the third quarter. KBC Group NV now owns 1,056 shares of the company’s stock worth $40,000 after purchasing an additional 519 shares during the period. R Squared Ltd bought a new position in USANA Health Sciences in the fourth quarter worth $28,000. Safe Harbor Fiduciary LLC bought a new position in USANA Health Sciences in the third quarter worth $30,000. Finally, Exchange Traded Concepts LLC lifted its position in USANA Health Sciences by 11.3% in the fourth quarter. Exchange Traded Concepts LLC now owns 8,578 shares of the company’s stock worth $308,000 after purchasing an additional 869 shares during the period. Institutional investors and hedge funds own 54.25% of the company’s stock.

USANA Health Sciences Company Profile

USANA Health Sciences, Inc develops, manufactures, and sells science-based nutritional, personal care, and skincare products in the Asia Pacific, the Americas, and Europe. The company offers USANA nutritional products that comprise essentials/CellSentials, such as vitamin and mineral supplements that provide a foundation of total body nutrition for various age groups; optimizers consisting of targeted supplements that are designed to meet cardiovascular, skeletal/structural, and digestive health needs; and food that include meal replacement shakes, snack bars, and other related products.